← Back to Clinical Trials
Recruiting NCT06878287

NCT06878287 Bright Light Therapy During Residential Alcohol Withdrawal

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06878287
Status Recruiting
Phase
Sponsor Centre Hospitalier St Anne
Condition Alcohol Use Disorder
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2022-05-31
Primary Completion 2025-05-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Light exposurePlacebo light

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2022-05-31 with a primary completion date of 2025-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a randomized controlled trial assessing the effectiveness of light therapy versus placebo in patients undergoing alcohol withdrawal.

Eligibility Criteria

Inclusion Criteria: * Patients must be aged from 18 to 65 years old and have a diagnosis of Alcohol Use Disorder * Patients must be intreated for alcohol withdrawal, for at least two weeks * Patients must report heavy drinking episodes in the past month * Patients must be able to understand medical information and consent to the treatment * Patients must be considering a goal of abstinence from alcohol Exclusion Criteria: * Ophthalmic pathology (cataract, macular degeneration, glaucoma, retinitis pigmentosa) and diseases affecting the retina (retinopathy, diabetes, herpes, etc.) * Subjects who have already received light therapy in the last 6 months * Lactating of pregnant women * Psychiatric comorbidity requiring an intreatment, or risk of manic episode (subjects with depressive or anxious symptoms compatible with an out-treatment can be included) * Substance Use Disorder other than alcohol and/or tobacco * Severe cognitive impairment (MOCA \< 10) * Patients being under legal protection measure

Contact & Investigator

Central Contact

Pierre Alexis GEOFFROY, PhD

✉ pierrealexis.geoffroy@aphp.fr

📞 +33140256048

Principal Investigator

Pierre Alexis GEOFFROY, PhD

PRINCIPAL INVESTIGATOR

University Hospital Group for Psychiatry and Neurosciences

Frequently Asked Questions

Who can join the NCT06878287 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Alcohol Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06878287 currently recruiting?

Yes, NCT06878287 is actively recruiting participants. Contact the research team at pierrealexis.geoffroy@aphp.fr for enrollment information.

Where is the NCT06878287 trial being conducted?

This trial is being conducted at Paris, France.

Who is sponsoring the NCT06878287 clinical trial?

NCT06878287 is sponsored by Centre Hospitalier St Anne. The principal investigator is Pierre Alexis GEOFFROY, PhD at University Hospital Group for Psychiatry and Neurosciences. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology